MoonLake Immunotherapeutics launches $200M public offering of 9M shares at $20.00 each

MoonLake Immunotherapeutics

Offering consists of 9,000,000 Class A ordinary shares at $20.00/share plus pre-funded warrants for up to 1,000,000 shares at $19.9999 each.
Underwriters granted 30-day option to purchase up to 1,500,000 additional shares at the offering price less discounts.
Gross proceeds expected to be $200 million before underwriting discounts and offering expenses.
Offering expected to close June 25, 2026; securities sold under effective shelf registration statement (File No. 333-274286).
Pre-funded warrants exercisable immediately at $0.0001/share, subject to beneficial ownership limitations (4.99% default).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.